FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS

THURSDAY, Sept. 26, 2024-- The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing and progressive...